Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bi-weekly docetaxel + cisplatin + S-1 (DCS) as first-line therapy for advanced esophageal cancer
jRCTs031180376Phase 2Recruiting
- Start
- Oct 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin and tegafur in esophageal cancer. Primary endpoints: Dose-limiting toxicity (DLT) and Progression-free survival (PFS). Started Oct 2017; status: recruiting.
02
Drugs
docetaxelcisplatintegafur
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCTs031180376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180376.